Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology

JAMA Psychiatry

Volumn 71, Issue 11, 2014, Pages 1262-1270

  Pietrzak, Robert H ^a,b   Naganawa, Mika ^b   Huang, Yiyun ^b   Corsi Travali, Stefani ^c   Zheng, Ming Qiang ^b   Stein, Murray B ^d,e   Henry, Shannan ^b   Lim, Keunpoong ^b   Ropchan, Jim ^b   Lin, Shu Fei ^b   Carson, Richard E ^b   Neumeister, Alexander ^c,f  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Steven and Alexandra Cohen Children's Medical Center of New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; KAPPA OPIATE RECEPTOR; LY 2795050 C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3-CHLORO-4-(4-((2-(3-PYRIDYL)PYRROLIDIN-1-YL)METHYL)PHENOXY)BENZAMIDE; BENZAMIDE DERIVATIVE; CARBON; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYDROCORTISONE URINE LEVEL; IN VIVO STUDY; MAJOR DEPRESSION; MALE; PATH ANALYSIS; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PRINCIPAL COMPONENT ANALYSIS; VOLUME OF DISTRIBUTION; AMYGDALOID NUCLEUS; CASE CONTROL STUDY; COMPLICATION; CORPUS STRIATUM; DEPRESSION; DIAGNOSTIC USE; FUNCTIONAL NEUROIMAGING; INJURY; METABOLISM; NERVE TRACT; PHOBIA; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; URINE; YOUNG ADULT;

ADULT; AMYGDALA; BENZAMIDES; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; FUNCTIONAL NEUROIMAGING; GYRUS CINGULI; HUMANS; HYDROCORTISONE; MALE; NEURAL PATHWAYS; PHOBIC DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; STRESS DISORDERS, POST-TRAUMATIC; VENTRAL STRIATUM; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84910081688     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1221     Document Type: Article

References (67)

1. Grant DM, Beck JG, Marques L, Palyo SA, Clapp JD. The structure of distress following trauma: posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder. J Abnorm Psychol. 2008;117(3):662-672.
2. Zoellner LA, Pruitt LD, Farach FJ, Jun JJ. Understanding heterogeneity in PTSD: fear, dysphoria, and distress. Depress Anxiety. 2014;31 (2):97-106.
3. Pietrzak RH, Gallezot JD, Ding YS, et al. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry. 2013;70(11):1199-1205.
4. Morris SE, Cuthbert BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012;14(1):29-37.
5. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.
6. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13(1):28-35.
7. Land BB, Bruchas MR, Schattauer S, et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A. 2009;106(45):19168-19173.
8. Bruchas MR, Land BB, Aita M, et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioiddependent dysphoria. J Neurosci. 2007;27(43): 11614-11623.
9. Muschamp JW, Van't Veer A, Parsegian A, et al. Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci. 2011;31(8):3095-3103.
10. Newton SS, Thome J,Wallace TL, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci. 2002;22(24):10883-10890.
11. BruchasMR, Land BB, Lemos JC, Chavkin C. CRF1-R activation of the dynorphin/kappa opioid systemin the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One. 2009;4(12):e8528.
12. Knoll AT, Muschamp JW, Sillivan SE, et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry. 2011;70(5):425-433.
13. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008;28(2): 407-414.
14. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003;305(1):323-330.
15. Carr GV, Bangasser DA, Bethea T, YoungM, Valentino RJ, Lucki I. Antidepressant-like effects of kappa-opioid receptor antagonists inWistar Kyoto rats. Neuropsychopharmacology. 2010;35(3):752-763.
16. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev. 2012;32 (4):301-315.
17. Van't Veer A, Yano JM, Carroll FI, Cohen BM, CarlezonWA Jr. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the opioid receptor antagonist JDTic. Neuropsychopharmacology. 2012;37(13):2809-2816.
18. WittmannW, Schunk E, Rosskothen I, et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology. 2009;34(3):775-785.
19. Chen Y, Chen C,Wang Y, Liu-Chen LY. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J Pharmacol Exp Ther. 2006;319(2):765-775.
20. AkilH,WatsonSJ,YoungE,LewisME,Khachaturian H,WalkerJM.Endogenousopioids:biologyandfunction. Annu Rev Neurosci. 1984;7:223-255.
21. Hiller JM, Fan LQ. Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Neurochem Res. 1996;21(11):1333-1345.
22. Simonin F, Gaveriaux-Ruff C, Befort K, et al. kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A. 1995;92(15):7006-7010.
23. Villarreal G, King CY. Brain imaging in posttraumatic stress disorder. Semin Clin Neuropsychiatry. 2001;6(2):131-145.
24. ZhengMQ, Nabulsi N, Kim SJ, et al. Synthesis and evaluation of 11C-LY2795050 as a opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013;54(3):455-463.
25. Kim SJ, ZhengMQ, Nabulsi N, et al. Determination of the in vivo selectivity of a new opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey. J Nucl Med. 2013;54(9):1668-1674.
26. Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain. 2008;131(pt 5):1171-1196.
27. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314:44-55.
28. Tejeda HA, Chefer VI, Zapata A, Shippenberg TS. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Psychopharmacology (Berl). 2010;210(2):231-240.
29. Kubany ES, Haynes SN, Leisen MB, et al. Development and preliminary validation of a brief broad-spectrum measure of trauma exposure: the Traumatic Life Events Questionnaire. Psychol Assess. 2000;12(2):210-224.
30. First MB, Spitzer RL, Gibbons M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY: New York State Psychiatric Institute, Biometrics Research; 1995.
31. Blake DD,Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
32. Montgomery SA, AsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
33. HamiltonM. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
34. King DW, Leskin GA,Weathers FW. Confirmatory factor analysis of the Clinician-Administered PTSD Scale: evidence for the dimensionality of posttraumatic stress disorder. Psychol Assess. 1998;10(2):90-96.
35. Parker RD, Flint EP, Bosworth HB, Pieper CF, Steffens DC. A three-factor analytic model of the MADRS in geriatric depression. Int J Geriatr Psychiatry. 2003;18(1):73-77.
36. Serretti A, Jori MC, Casadei G, Ravizza L, Smeraldi E, Akiskal H. Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. J Affect Disord. 1999;56(1):17-25.
37. Beck AT, Steer RA. Relationship between the Beck Anxiety Inventory and the Hamilton Anxiety Rating Scale with anxious outpatients. J Anxiety Disord. 1991;5(3):213-223. doi:10.1016/0887-6185(91) 90002-B.
38. Neumeister A, NormandinMD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034-1040.
39. Papademetris X, Jackowski M, Rajeevan N, Constable RT, Staib LH. BioImage suite: an integrated medical image analysis suite. Insight J. 2005;1.
40. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22(10):1271-1281.
41. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav ResMethods. 2008;40(3):879-891.
42. Forbes D, Lockwood E, Elhai JD, et al. An examination of the structure of posttraumatic stress disorder in relation to the anxiety and depressive disorders. J Affect Disord. 2011;132(1-2): 165-172.
43. Forbes D, Parslow R, Creamer M, et al. A longitudinal analysis of posttraumatic stress disorder symptoms and their relationship with fear and anxious-misery disorders: implications for DSM-V. J Affect Disord. 2010;127(1-3):147-152.
44. Mason JW,Wang S, Yehuda R, Riney S, Charney DS, Southwick SM. Psychogenic lowering of urinary cortisol levels linked to increased emotional numbing and a shame-depressive syndrome in combat-related posttraumatic stress disorder. Psychosom Med. 2001;63(3):387-401.
45. Horn CA, Pietrzak RH, Corsi-Travali S, Neumeister A. Linking plasma cortisol levels to phenotypic heterogeneity of posttraumatic stress symptomatology. Psychoneuroendocrinology. 2014; 39:88-93.
46. Tejeda HA, Counotte DS, Oh E, et al. Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology. 2013;38(9):1770-1779.
47. Watanabe H, Fitting S, Hussain MZ, et al. Asymmetry of the endogenous opioid system in the human anterior cingulate: a putative molecular basis for lateralization of emotions and pain [published online August 19, 2013]. Cereb Cortex.
48. Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 2010;15(6):574-588.
49. Knoll AT, CarlezonWA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56-73.
50. Sirinathsinghji DJ, Nikolarakis KE, Herz A. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostriatum and globus pallidus of the rat: in vitro and in vivo studies. Brain Res. 1989;490(2): 276-291.
51. Leitl MD, Onvani S, Bowers MS, et al. Pain-related depression of themesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous kappa-opioids. Neuropsychopharmacology. 2013;39(3):614-624.
52. Schell TL, Marshall GN, Jaycox LH. All symptoms are not created equal: the prominent role of hyperarousal in the natural course of posttraumatic psychological distress. J Abnorm Psychol. 2004;113(2):189-197.
53. Marshall GN, Schell TL, Glynn SM, Shetty V. The role of hyperarousal in the manifestation of posttraumatic psychological distress following injury. J Abnorm Psychol. 2006;115(3):624-628.
54. Thompson KE, Vasterling JJ, Benotsch EG, et al. Early symptom predictors of chronic distress in GulfWar veterans. J Nerv Ment Dis. 2004;192(2): 146-152.
55. Malta LS,Wyka KE, Giosan C, Jayasinghe N, Difede J. Numbing symptoms as predictors of unremitting posttraumatic stress disorder. J Anxiety Disord. 2009;23(2):223-229.
56. Pietrzak RH, Goldstein MB, Malley JC, Rivers AJ, Southwick SM. Structure of posttraumatic stress disorder symptoms and psychosocial functioning in Veterans of Operations Enduring Freedom and Iraqi Freedom. Psychiatry Res. 2010;178(2):323-329.
57. Kuhn E, Blanchard EB, Hickling EJ. Posttraumatic stress disorder and psychosocial functioning within two samples of MVA survivors. Behav Res Ther. 2003;41(9):1105-1112.
58. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology. 2006;31(4):787-794.
59. Carr GV, Lucki I. Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology (Berl). 2010;210(2):295-302.
60. Knoll AT, Meloni EG, Thomas JB, Carroll FI, CarlezonWA Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther. 2007;323(3):838-845.
61. Sauriyal DS, Jaggi AS, Singh N. Extending pharmacological spectrum of opioids beyond analgesia: multifunctional aspects in different pathophysiological states. Neuropeptides. 2011;45 (3):175-188.
62. Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, CarlezonWA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62(1): 167-176.
63. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165(5):617-620.
64. Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010;27(5):417-425.
65. Carroll FI, CarlezonWA Jr. Development of opioid receptor antagonists. J Med Chem. 2013;56 (6):2178-2195.
66. BarrotM, Olivier JD, Perrotti LI, et al. CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. ProcNatl Acad Sci U S A. 2002;99(17):11435-11440.
67. CarlezonWA Jr, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci. 2005;28(8): 436-445.